Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cyto...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Anne-Priscille Trouvin, Vincent Goëb
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Osteoprotegerin
RANK
RANKL
Denosumab
Strontium ranelate
Osteoporosis
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/1d621b844c5b47c2b20e107b72a9fbe1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1d621b844c5b47c2b20e107b72a9fbe1
record_format dspace
spelling oai:doaj.org-article:1d621b844c5b47c2b20e107b72a9fbe12021-12-02T06:08:09ZReceptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss1178-1998https://doaj.org/article/1d621b844c5b47c2b20e107b72a9fbe12010-11-01T00:00:00Zhttps://www.dovepress.com/receptor-activator-of-nuclear-factor-kappab-ligand-and-osteoprotegerin-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway OPG/RANK/RANKL is key to regulation for maintaining the balance between the activity of osteoblasts and osteoclasts in order to prevent bone loss and ensure a normal bone turnover. In this review, the RANK/RANKL/OPG pathway is described. The multiple interactions of various factors (hormones, cytokines, growth factors, and vitamins) with the OPG/RANK/RANKL pathway are also commented on. Finally, the effects of denosumab, a human monoclonal antibody that binds to RANKL and thereby inhibits the activation of osteoclasts, and of strontium ranelate are also described. Indeed, these two new drugs afford appreciable assistance in daily care practice, helping to prevent bone loss in patients with osteoporosis.Keywords: osteoprotegerin, OPG, RANK, RANKL, denosumab, strontium ranelate, osteoporosisAnne-Priscille TrouvinVincent GoëbDove Medical PressarticleOsteoprotegerinRANKRANKLDenosumabStrontium ranelateOsteoporosisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 345-354 (2010)
institution DOAJ
collection DOAJ
language EN
topic Osteoprotegerin
RANK
RANKL
Denosumab
Strontium ranelate
Osteoporosis
Geriatrics
RC952-954.6
spellingShingle Osteoprotegerin
RANK
RANKL
Denosumab
Strontium ranelate
Osteoporosis
Geriatrics
RC952-954.6
Anne-Priscille Trouvin
Vincent Goëb
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
description Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation. It is a complex process that involves numerous factors: hormones, growth factors, vitamins, and cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB (RANK) ligand. The signaling pathway OPG/RANK/RANKL is key to regulation for maintaining the balance between the activity of osteoblasts and osteoclasts in order to prevent bone loss and ensure a normal bone turnover. In this review, the RANK/RANKL/OPG pathway is described. The multiple interactions of various factors (hormones, cytokines, growth factors, and vitamins) with the OPG/RANK/RANKL pathway are also commented on. Finally, the effects of denosumab, a human monoclonal antibody that binds to RANKL and thereby inhibits the activation of osteoclasts, and of strontium ranelate are also described. Indeed, these two new drugs afford appreciable assistance in daily care practice, helping to prevent bone loss in patients with osteoporosis.Keywords: osteoprotegerin, OPG, RANK, RANKL, denosumab, strontium ranelate, osteoporosis
format article
author Anne-Priscille Trouvin
Vincent Goëb
author_facet Anne-Priscille Trouvin
Vincent Goëb
author_sort Anne-Priscille Trouvin
title Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_short Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_full Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_fullStr Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_full_unstemmed Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
title_sort receptor activator of nuclear factor-κb ligand and osteoprotegerin: maintaining the balance to prevent bone loss
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/1d621b844c5b47c2b20e107b72a9fbe1
work_keys_str_mv AT annepriscilletrouvin receptoractivatorofnuclearfactorkappabligandandosteoprotegerinmaintainingthebalancetopreventboneloss
AT vincentgoeumlb receptoractivatorofnuclearfactorkappabligandandosteoprotegerinmaintainingthebalancetopreventboneloss
_version_ 1718400039598948352

Ejemplares similares